## Paul Griffin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12067944/publications.pdf

Version: 2024-02-01

		1684188	2053705	
5	2,198	5	5	
papers	citations	h-index	g-index	
5	5	5	4873	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	9.1	82
2	Phase 1â€"2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine, 2020, 383, 2320-2332.	27.0	1,000
3	New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation. Antimicrobial Agents and Chemotherapy, 2009, 53, 5080-5087.	3.2	53
4	Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications. Methods in Enzymology, 2009, 460, 17-55.	1.0	16
5	Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrobial Agents and Chemotherapy, 2005, 49, 4721-4732.	3.2	1,047